首页|辅酶Q10联合法舒地尔治疗冠心病不稳定型心绞痛患者的临床效果

辅酶Q10联合法舒地尔治疗冠心病不稳定型心绞痛患者的临床效果

扫码查看
目的 分析辅酶Q10 联合法舒地尔治疗冠心病不稳定型心绞痛患者的临床效果.方法 选取2020年 8月至 2022 年 8 月收治的 92 例冠心病不稳定型心绞痛患者为研究对象,以随机法将其分为常规组(46 例,法舒地尔治疗)和观察组(46例,辅酶Q10联合法舒地尔治疗).比较两组的治疗效果.结果 观察组的治疗总有效率为97.83%,高于常规组的 84.78%,差异具有统计学意义(P<0.05).治疗后,观察组的脑钠肽(BNP)、心肌肌钙蛋白T(cTnT)、可溶性生长刺激表达基因 2 蛋白(sST2)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、同型半胱氨酸(HCY)、胸腺基质淋巴细胞生成素(TSLP)及内皮素(ET)水平低于常规组,脂联素(APN)、一氧化氮(NO)水平高于常规组,差异具有统计学意义(P<0.05).治疗后,观察组的CD4+、CD4+/CD8+高于常规组,CD8+低于常规组,差异具有统计学意义(P<0.05).两组治疗期间的药物不良反应总发生率比较,差异无统计学意义(P>0.05).结论 辅酶Q10 联合法舒地尔治疗冠心病不稳定型心绞痛患者可有效促进心肌损伤修复,减轻炎症反应,调节免疫功能,促使病情快速转归,且不会增加不良反应发生率,属于安全高效的治疗方案,值得临床推广与应用.
Clinical effect of coenzyme Q10 combined with fasudil in the treatment of patients with unstable angina pectoris of coronary heart disease
Objective To analyze the clinical effect of coenzyme Q10 combined with fasudil in the treatment of patients with unstable angina pectoris of coronary heart disease.Methods A total of 92 patients with unstable angina pectoris of coronary heart disease admitted from August 2020 to August 2022 were selected as the research objects and divided into routine group(46 cases,fasudil treatment)and observation group(46 cases,coenzyme Q10 combined with fasudil treatment)by random method.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was 97.83%,which was higher than 84.78%in the routine group,and the difference was statistically significant(P<0.05).After treatment,the levels of brain natriuretic peptide(BNP),cardiac troponin T(cTnT),soluble growth stimulator gene 2 protein(sST2),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),homocysteine(HCY),thymic stromal lymphopoietin(TSLP)and endothelin(ET)in the observation group were lower than those in the routine group,and the levels of adiponectin(APN)and nitric oxide(NO)were higher than those in the routine group,the differences were statistically significant(P<0.05).After treatment,the CD4+ and CD4+/CD8+in the observation group were higher than those in the routine group,and the CD8+ was lower than that in the routine group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse drug reactions between the two groups during treatment(P>0.05).Conclusion Coenzyme Q10 combined with fasudil in the treatment of patients with unstable angina pectoris of coronary heart disease can effectively promote the repair of myocardial injury,alleviate the inflammatory response,regulate the immune function,promote the rapid outcome of the disease,and does not increase the incidence of adverse reactions,which is a safe and efficient treatment regimen.It is worthy of clinical promotion and application.

coronary heart diseaseunstable angina pectorisfasudilcoenzyme Q10

董利洁、徐云鹏

展开 >

西安工会医院心血管内二科,陕西 西安,710199

延安大学咸阳医院心血管内科七病区,陕西 咸阳, 712000

冠心病 不稳定型心绞痛 法舒地尔 辅酶Q10

2024

临床医学研究与实践

临床医学研究与实践

ISSN:
年,卷(期):2024.9(13)
  • 14